Tuesday, organ transplant-medical device firm TransMedics Group Inc (NASDAQ:TMDX) reported first-quarter EPS of 35 cents, a turnaround from an EPS loss of 8 cents a year ago, beating the consensus of a loss of 5 cents.  The company reported sales of $96.85 million, up 133% Y/Y, beating the consensus of $83.8 million, primarily due to the increase in utilization of the Organ Care System (OCS) across all three organs through the National OCS Program (NOP) as well as additional revenue generated by the addition of TransMedics logistics services. The gross margin for the first quarter of 2024 was 62%, compared to 69% in the first quarter of 2023 and ...